CANNABIS SCIENCE, INC. (OTCMKTS:CBIS) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure |
The information in this report shall not be treated as filed for
purposes of the Securities Exchange Act of 1934, as amended.
Attached hereto as Exhibit 99.1 and incorporated by reference
herein is a press release of Cannabis Science, Inc. (the Company)
announcing that the Companys Subsidiary, Cannabis Science Europe
GmbH Acquires Majority Shares of German Bio Med GmbH Jinvator to
Facilitate European Expansions, New Products, and Additional
Clinical Studies.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
| Exhibit Number | Description of Exhibit |
|
99.1 |
Cannabis Science, Inc. Press Release dated April 5, 2017 |
About CANNABIS SCIENCE, INC. (OTCMKTS:CBIS)
Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV. CANNABIS SCIENCE, INC. (OTCMKTS:CBIS) Recent Trading Information
CANNABIS SCIENCE, INC. (OTCMKTS:CBIS) closed its last trading session down -0.0009 at 0.0801 with 10,754,427 shares trading hands.
